RT Journal Article
SR Electronic
T1 Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.09.22279759
DO 10.1101/2022.09.09.22279759
A1 Felicity Liew
A1 Shubha Talwar
A1 Andy Cross
A1 Brian J. Willett
A1 Sam Scott
A1 Nicola Logan
A1 Matthew K. Siggins
A1 Dawid Swieboda
A1 Jasmin K. Sidhu
A1 Claudia Efstathiou
A1 Shona C. Moore
A1 Chris Davis
A1 Noura Mohamed
A1 Jose Nunag
A1 Clara King
A1 A. A. Roger Thompson
A1 Sarah L. Rowland-Jones
A1 Annemarie B. Docherty
A1 James D. Chalmers
A1 Ling-Pei Ho
A1 Alexander Horsley
A1 Betty Raman
A1 Krisnah Poinasamy
A1 Michael Marks
A1 Onn Min Kon
A1 Luke Howard
A1 Daniel G. Wootton
A1 Susanna Dunachie
A1 Jennifer K. Quint
A1 Rachael A. Evans
A1 Louise V. Wain
A1 Sara Fontanella
A1 Thushan I. de Silva
A1 Antonia Ho
A1 Ewen Harrison
A1 J. Kenneth Baillie
A1 Malcolm G. Semple
A1 Christopher Brightling
A1 Ryan S. Thwaites
A1 Lance Turtle
A1 Peter J.M. Openshaw
A1 ISARIC4C Investigators and the PHOSP-COVID collaborative group
YR 2022
UL http://medrxiv.org/content/early/2022/09/09/2022.09.09.22279759.abstract
AB Background Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving limited insights into mucosal defences that prevent viral replication and onward transmission. We studied nasal and plasma antibody responses one year after hospitalisation for COVID-19, including a period when SARS-CoV-2 vaccination was introduced.Methods Plasma and nasosorption samples were prospectively collected from 446 adults hospitalised for COVID-19 between February 2020 and March 2021 via the ISARIC4C and PHOSP-COVID consortia. IgA and IgG responses to NP and S of ancestral SARS-CoV-2, Delta and Omicron (BA.1) variants were measured by electrochemiluminescence and compared with plasma neutralisation data.Findings Strong and consistent nasal anti-NP and anti-S IgA responses were demonstrated, which remained elevated for nine months. Nasal and plasma anti-S IgG remained elevated for at least 12 months with high plasma neutralising titres against all variants. Of 180 with complete data, 160 were vaccinated between 6 and 12 months; coinciding with rises in nasal and plasma IgA and IgG anti-S titres for all SARS-CoV-2 variants, although the change in nasal IgA was minimal. Samples 12 months after admission showed no association between nasal IgA and plasma IgG responses, indicating that nasal IgA responses are distinct from those in plasma and minimally boosted by vaccination.Interpretation The decline in nasal IgA responses 9 months after infection and minimal impact of subsequent vaccination may explain the lack of long-lasting nasal defence against reinfection and the limited effects of vaccination on transmission. These findings highlight the need to develop vaccines that enhance nasal immunity.Evidence before the study While systemic immunity to SARS-CoV-2 is important in preventing severe disease, mucosal immunity prevents viral replication at the point of entry and reduces onward transmission. We searched PubMed with search terms “mucosal”, “nasal”, “antibody”, “IgA”, “COVID-19”, “SARS-CoV-2”, “convalescent” and “vaccination” for studies published in English before 20th July 2022, identifying three previous studies examining the durability of nasal responses that generally show nasal antibody to persist for 3 to 9 months. However, these studies were small or included individuals with mild COVID-19. One study of 107 care-home residents demonstrated increased salivary IgG (but not IgA) after two doses of mRNA vaccine, and another examined nasal antibody responses after infection and subsequent vaccination in 20 cases, demonstrating rises in both nasal IgA and IgG 7 to 10 days after vaccination.Added value of this study Studying 446 people hospitalised for COVID-19, we show durable nasal and plasma IgG responses to ancestral (B.1 lineage) SARS-CoV-2, Delta and Omicron (BA.1) variants up to 12 months after infection. Nasal antibody induced by infection with pre-Omicron variants, bind Omicron virus in vitro better than plasma antibody. Although nasal and plasma IgG responses were enhanced by vaccination, Omicron binding responses did not reach levels equivalent to responses for ancestral SARS-CoV-2. Using paired plasma and nasal samples collected approximately 12 months after infection, we show that nasal IgA declines and shows a minimal response to vaccination whilst plasma antibody responses to S antigen are well maintained and boosted by vaccination.Implications of all the available evidence After COVID-19 and subsequent vaccination, Omicron binding plasma and nasal antibody responses are only moderately enhanced, supporting the need for booster vaccinations to maintain immunity against SARS-CoV-2 variants. Notably, there is distinct compartmentalisation between nasal IgA and plasma IgA and IgG responses after vaccination. These findings highlight the need for vaccines that induce robust and durable mucosal immunity.Competing Interest StatementA.A. Roger Thompson receives speaker fees and support to attend meetings from Janssen Pharmaceuticals. Sarah L. Rowland-Jones receives support from UKRI GCRF Rosetrees Trust BHIVA EDCTP and Globvac. She is on the data safety monitoring board for Bexero trial in HIV+ adults in Kenya. James D. Chalmers is the deputy chief editor of ERS. He receives consulting fees from AstraZeneca Boehringer Ingelheim Chiesi GlaxoSmithKline Insmed Janssen Novartis Pfizer and Zambon. He has grants from AstraZeneca Boehringer Ingelheim GlaxoSmithKline Gilead Sciences Grifols Novartis and Insmed. Ling-Pei Ho has no conflicts of interest. Alexander Horsley is Deputy chair of NIHR Translational Research Collaboration (unpaid role). He is currently supported by UK□Research and Innovation NIHR and NIHR Manchester BRC. Betty Raman receives support from BHF Oxford Centre of Research Excellence NIHR Oxford BRC and MRC. She receives honoraria from Axcella therapeutics. Krisnah Poinasamy has no conflicts of interest. Susanna J. Dunachie is supported by an NIHR Global Research Professorship (NIHR300791). She is a member of the PITCH Consortium which has received funding from UK Department of Health and Social Care. She receives support from UKRI as part of Investigation of proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN consortium & PITCH Plus Pathway (MR/W02067X/1), with contributions from UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC) the Huo Family Foundation and The National Institute for Health & Care Research (UKRIDHSC COVID-19 Rapid Response Rolling Call Grant Reference Number COV19-RECPLAS). S.J.D. is a Scientific Advisor to the Scottish Parliament on COVID-19 for which she receives a fee. SJD also receives support from UKRI Huo family foundation and NIHR England. Rachael A. Evans is co-lead of PHOSP-COVID and receives funding from UKRI and NIHR for this study. She also receives fees from Astrazenaca / Evidera for consultancy on Long Covid and from Astrazenaca for consultancy on digital health. She has received speaker fees from Boehringer and has held a role as European Respiratory Society Assembly 01.02 Pulmonary Rehabilitation secretary and is on the American Thoracic Society Pulmonary Rehabilitation Assembly programme committee. Louise V. Wain has received support from UKRI GSK/Asthma + Lung UK and NIHR for this study. She also receives funding from Orion pharma and GSK. She holds contracts with Genentech and AstraZenaca. She has received consulting fees from Galapagos and Boehringer. She is on the data advisory board for Galapagos and is Associate Editor for European Respiratory Journal. Thushan I de Silva has no conflicts of interest. Antonia Ho has received support from MRC and for the Coronavirus Immunology Consortium (MR/V028448/1) and is a member of NIHR Urgent Public Health Group (June 2020-March 2021). Malcolm G. Semple has received support from NIHR UK MRC UK and Health Protection Research Unit in Emerging & Zoonotic Infections University of Liverpool. He acts as an independent external and non-remunerated member of Pfizer External Data Monitoring Committee for their mRNA vaccine program(s). He is Chair of Infectious Disease Scientific Advisory Board of Integrum Scientific LLC, Greensboro, NC, USA. He is director of MedEx Solutions Ltd and majority owner of MedEx Solutions Ltd and minority owner of Integrum Scientific LLC, Greensboro, NC, USA. His institution has been in receipt of gifts from Chiesi Farmaceutici S.p.A. of Clinical Trial Investigational Medicinal Product without encumbrance and distribution of same to trial sites. He is a non-renumerated member of HMG UK New Emerging Respiratory Virus Threats Advisory Group (NERVTAG) and has previously been a non-renumerated member of SAGE. Christopher Brightling has received funds from MRC, NIHR and Leicester NIHR BRC to support the PHOSP-COVID study. He has received consulting fees and/or grants from GSK, AZ, Genentech, Roche, Novartis, Sanofi, Regeneron, Chiesi, Mologic and 4DPharma. Ryan S. Thwaites has no conflicts of interest. Lance Turtle is supported by grants from MRC, NIHR, Wellcome Trust, FDA and DHSC. He has received consulting fees from MHRA and speak fees from Eisai Ltd. He has a patent pending with ZikaVac. PJMO reports grants from the EU Innovative Medicines Initiative (IMI) 2 Joint Undertaking during the submitted work; grants from UK Medical Research Council, GlaxoSmithKline, Wellcome Trust, EU-IMI, UK, National Institute for Health Research, and UK Research and Innovation-Department for Business, Energy and Industrial Strategy; and personal fees from Pfizer, Janssen, and Seqirus, outside the submitted work.Clinical Protocols https://phosp.org/resource/.Funding StatementThis research used data assets made available by Outbreak Data Analysis Platform (ODAP) as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). This work is supported by the following grants: The PHOSP-COVD study is jointly funded by UK Research and Innovation and National Institute of Health and Care Research (grant references: MR/V027859/1 and COV0319). ISARIC4C is supported by grants from the National Institute for Health and Care Research (award CO-CIN-01) and the Medical Research Council (grant MC_PC_19059) Liverpool Experimental Cancer Medicine Centre provided infrastructure support for this research (grant reference: C18616/A25153). Other grants which have supported this work include: the UK Coronavirus Immunology Consortium [funder reference:1257927], the Imperial Biomedical Research Centre (NIHR Imperial BRC, grant IS-BRC-1215-20013), the Health Protection Research Unit (HPRU) in Respiratory Infections at Imperial College London and NIHR HPRU in Emerging and Zoonotic Infections at University of Liverpool, both in partnership with Public Health England, [NIHR award 200907], Wellcome Trust and Department for International Development [215091/Z/18/Z], Health Data Research UK (HDR UK) [grant code: 2021.0155], Medical Research Council [grant code: MC_UU_12014/12], and NIHR Clinical Research Network for providing infrastructure support for this research. FL is supported by an MRC clinical training fellowship [award MR/W000970/1]. LPH is supported by Oxford NIHR Biomedical Research Centre. AART is supported by a BHF Intermediate Clinical Fellowship (FS/18/13/33281). RAE holds a NIHR Clinician Scientist Fellowship (CS-2016-16-020). SD is funded by an NIHR Global Research Professorship [NIHR300791]. DW is supported by an NIHR Advanced Fellowship. PJMO is supported by a NIHR Senior Investigator Award [award 201385]. LT is supported by the Wellcome Trust [clinical career development fellowship grant number 205228/Z/16/Z], the Centre of Excellence in Infectious Diseases Research (CEIDR) and the Alder Hey Charity. The funders were not involved in the study design, interpretation of data or writing of this manuscript. The views expressed are those of the authors and not necessarily those of the DHSC, DID, NIHR, MRC, the Wellcome Trust, UK-HAS, the National Health Service, or the Department of Health. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a combined ISARIC4C and PHOSPCOVID study. Written informed consent was obtained from all patients within ISARIC4C. Ethical approval was given by the South Central Oxford C Research Ethics Committee in England (reference: 13/SC/0149), Scotland A Research Ethics Committee (20/SS/0028) and World Health Organization Ethics Review Committee (RPC571 and RPC572l; 25 April 2013). Written informed consent was obtained from all patients for the PHOSP-COVID study. Ethical approvals for the PHOSPCOVID study were given by Leeds West Research Ethics Committee (20/YH/0225).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe ISARIC4C protocol, data sharing and publication policy are available at https://isaric4c.net. ISARIC4C Independent Data and Material Access Committee welcomes applications for access to data and materials (https://isaric4c.net). The PHOSP-COVID protocol, consent form, definition and derivation of clinical characteristics and outcomes, training materials, regulatory documents, information about requests for data access, and other relevant study materials are available online: https://phosp.org/resource/. Access to these materials can be granted by contacting the PHOSP-COVID collaborative group. https://phosp.org/resource/. https://isaric4c.net.